» Articles » PMID: 15452286

Motor Signs During the Course of Alzheimer Disease

Overview
Journal Neurology
Specialty Neurology
Date 2004 Sep 29
PMID 15452286
Citations 82
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Motor signs (MOSIs) are common in Alzheimer disease (AD) and may be associated with rates of cognitive decline, mortality, and cost of care.

Objective: To describe the progression and identify predictors of individual MOSIs in AD.

Methods: A cohort of 474 patients with AD at early stages was followed semiannually for up to 13.1 years (mean 3.6 years) in five centers in Europe and the United States. MOSIs were rated using a standardized portion of the Unified Parkinson's Disease Rating Scale. Overall, 3,030 visits/assessments of MOSIs (average 6.4/patient) were performed. Prevalence and incidence rates were calculated, and cumulative risk graphs were plotted for individual non-drug-induced MOSI domains. Rates of change over time taking into account potential covariates were also estimated. With use of each MOSI domain as outcome in Cox models, predictors of MOSI incidence were identified.

Results: At least one MOSI was detected in 13% of patients at first examination and in 36% for the last evaluation. Total MOSI score increased at an annual rate of 3% of total possible score. Rates of annual change for speech/facial expression (4%), rigidity (2.45%), posture/gait (3.9%), and bradykinesia (3.75%) were of similar magnitude, and their occurrence increased from first (3 to 6%) to last (22 to 29%) evaluation. Tremor was less frequent throughout the course of the disease (4% at first and 7% at last evaluation) and worsened less (0.75% increase/year).

Conclusions: Most motor signs occur frequently and progress rapidly in Alzheimer disease. Tremor is an exception in that it occurs less frequently and advances at slower rates.

Citing Articles

Alzheimer's disease: a comprehensive review of epidemiology, risk factors, symptoms diagnosis, management, caregiving, advanced treatments and associated challenges.

Safiri S, Ghaffari Jolfayi A, Fazlollahi A, Morsali S, Sarkesh A, Daei Sorkhabi A Front Med (Lausanne). 2024; 11:1474043.

PMID: 39736972 PMC: 11682909. DOI: 10.3389/fmed.2024.1474043.


Alzheimer's Disease: Understanding Motor Impairments.

Andrade-Guerrero J, Martinez-Orozco H, Villegas-Rojas M, Santiago-Balmaseda A, Delgado-Minjares K, Perez-Segura I Brain Sci. 2024; 14(11).

PMID: 39595817 PMC: 11592238. DOI: 10.3390/brainsci14111054.


Progressive cervical cord atrophy parallels cognitive decline in Alzheimer's disease.

Emmenegger T, Seiler R, Unschuld P, Freund P, Klohs J Sci Rep. 2024; 14(1):21595.

PMID: 39284823 PMC: 11405669. DOI: 10.1038/s41598-024-67389-9.


Classification of Mild Cognitive Impairment and Alzheimer's Disease Using Manual Motor Measures.

Koppelmans V, Ruitenberg M, Schaefer S, King J, Jacobo J, Silvester B Neurodegener Dis. 2024; 24(2):54-70.

PMID: 38865972 PMC: 11381162. DOI: 10.1159/000539800.


Spatiotemporal development of the neuronal accumulation of amyloid precursor protein and the amyloid plaque formation in the brain of 3xTg-AD mice.

Ono M, Ito T, Yamaki S, Hori Y, Zhou Q, Zhao X Heliyon. 2024; 10(7):e28821.

PMID: 38596059 PMC: 11002285. DOI: 10.1016/j.heliyon.2024.e28821.


References
1.
Wilson R, Bennett D, Gilley D, Beckett L, Schneider J, Evans D . Progression of parkinsonian signs in Alzheimer's disease. Neurology. 2000; 54(6):1284-9. DOI: 10.1212/wnl.54.6.1284. View

2.
HEYMAN A, Fillenbaum G, Gearing M, Mirra S, Welsh-Bohmer K, Peterson B . Comparison of Lewy body variant of Alzheimer's disease with pure Alzheimer's disease: Consortium to Establish a Registry for Alzheimer's Disease, Part XIX. Neurology. 1999; 52(9):1839-44. DOI: 10.1212/wnl.52.9.1839. View

3.
Stern Y, Jacobs D, Goldman J, Gomez-Tortosa E, Hyman B, Liu Y . An investigation of clinical correlates of Lewy bodies in autopsy-proven Alzheimer disease. Arch Neurol. 2001; 58(3):460-5. DOI: 10.1001/archneur.58.3.460. View

4.
Haan M, Jagust W, Galasko D, Kaye J . Effect of extrapyramidal signs and Lewy bodies on survival in patients with Alzheimer disease. Arch Neurol. 2002; 59(4):588-93. DOI: 10.1001/archneur.59.4.588. View

5.
Scarmeas N, Brandt J, Albert M, Devanand D, Marder K, Bell K . Association between the APOE genotype and psychopathologic symptoms in Alzheimer's disease. Neurology. 2002; 58(8):1182-8. PMC: 3029097. DOI: 10.1212/wnl.58.8.1182. View